Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] New guideline for idiopathic pulmonary fibrosis

The Lancet Editors (July 25, p 312)1 highlight the publication of a new international clinical guideline for the treatment of idiopathic pulmonary fibrosis.2 This updated guideline provides conditional recommendations for use of nintedanib and pirfenidone to treat patients with idiopathic pulmonary fibrosis and emphasises the role of individual patients’ preferences and values in treatment decisions.2 According to the Editors, this guideline suggests that nintedanib and pirfenidone might be suitable for some patients, whereas the conditional recommendation, according to the guideline, is when “the majority of individuals in this situation would want the suggested course of action, but many would not”.